{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:58:54Z","timestamp":1790539134738,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470144"],"award-info":[{"award-number":["82470144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.08.017","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:36:54Z","timestamp":1788190614000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Single-center Retrospective Study of MIAD \u00b1 R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes"],"prefix":"10.1016","author":[{"given":"Yuedan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-8862","authenticated-orcid":false,"given":"Qu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-7572","authenticated-orcid":false,"given":"Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2026.08.017_bib0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjh.12938","article-title":"Progress in central nervous system lymphomas","volume":"166","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.017_bib0002","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.clml.2026.08.017_bib0003","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2011.357","article-title":"Age, gender, and racial differences in incidence and survival in primary CNS lymphoma","volume":"105","author":"Vilano","year":"2011","journal-title":"Br J Cancer"},{"issue":"31","key":"10.1016\/j.clml.2026.08.017_bib0004","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.017_bib0005","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.08.017_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.08.017_bib0007","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.08.017_bib0008","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous trans- plant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.08.017_bib0009","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.16451","article-title":"Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system\u2014an international study of feasibility and efficacy in routine clinical practice","volume":"189","author":"Schorb","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.08.017_bib0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/mco.2015.566","article-title":"Immunochemotherapy for primary central nervous system lymphoma with rituximab, methotrexate, cytarabine and dexamethasone: retrospective analysis of 18 cases","volume":"3","author":"Liu","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"30","key":"10.1016\/j.clml.2026.08.017_bib0011","doi-asserted-by":"crossref","first-page":"49156","DOI":"10.18632\/oncotarget.17101","article-title":"Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.clml.2026.08.017_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-010-1274-4","article-title":"Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies","volume":"67","author":"Kiewe","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.017_bib0013","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0277-5379(87)90075-7","article-title":"Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas","volume":"23","author":"Bramwell","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108366","article-title":"Ifosfamide. History, efficacy, toxicity and encephalopathy","volume":"243","author":"Idle","year":"2023","journal-title":"Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.clml.2026.08.017_bib0015","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.08.017_bib0016","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.08.017_bib0017","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.08.017_bib0018","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hon.3083","article-title":"Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: a systematic review and meta-analysis","volume":"41","author":"Epperla","year":"2023","journal-title":"Hematol Oncol"},{"issue":"24","key":"10.1016\/j.clml.2026.08.017_bib0019","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1182\/bloodadvances.2024013780","article-title":"Evolving consolidation patterns and outcomes for a large cohort of patients with primary CNS lymphoma","volume":"8","author":"Tringale","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2026.08.017_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.08.017_bib0021","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2003.00045.x","article-title":"Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma","volume":"70","author":"Arellano-Rodrigo","year":"2003","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.08.017_bib0022","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hon.2037","article-title":"Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy","volume":"31","author":"Mappa","year":"2013","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.08.017_bib0023","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/bloodadvances.2024014373","article-title":"ICE polychemotherapy is an efficient salvage treatment in primary central nervous system lymphoma: an LOC network study","volume":"9","author":"P\u00e9rol","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.08.017_bib0024","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/bjh.18687","article-title":"Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience","volume":"201","author":"Ostrowska","year":"2023","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:53:23Z","timestamp":1790538803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S2152265026032854"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Single-center Retrospective Study of MIAD \u00b1 R Chemotherapy in Newly Diagnosed Primary Central Nervous System Lymphoma: Safety Profiles and Clinical Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}